Immunovant (IMVT) total assets

Total assets · fiscal 2026
$957.01M

Immunovant (IMVT) had total assets of $957.01M at the end of fiscal 2026 (March 31, 2026). That is 23.3% higher than the $776.22M of fiscal 2025. Figures as of 17 Nov 2026, 23:55 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total assets, fiscal 2026
$957.01M
Change on fiscal 2025
+23.3%
Growth, 5 years
+18.3% a year
Highest on record
$957.01Mfiscal 2026
Lowest on record
$13.83Mfiscal 2019
Fiscal years on record
82019–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Immunovant total assets, in more detail

Over the five fiscal years to 2026 total assets grew at a compound 18.3% a year. Across the 8 fiscal years on record (2019–2026), the highest was $957.01M in fiscal 2026 and the lowest $13.83M in fiscal 2019.

History · 8 fiscal years

Total assets by fiscal year

Immunovant total assets, year by year

Immunovant (IMVT) total assets by fiscal year
Fiscal yearTotal assetsChangeYear ended
2026$957.01M 23.3% up
2025$776.22M 16.5% up
2024$666.37M 64.2% up
2023$405.84M 21.3% down
2022$515.56M 25.0% up
2021$412.49M 277.1% up
2020$109.39M 691.1% up
2019$13.83M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total assets is everything on the balance sheet at the fiscal year-end — cash, receivables, inventory, property, goodwill and the rest.

How to read it

It measures the resources the business has put to work; assets that grow faster than profit mean each new unit of investment is earning less.

Total assets at health care companies of similar size

Total assets of Immunovant and comparable companies
CompanyTotal assetsFiscal year
Bausch + Lomb BLCO$14.02B2025
Amneal Pharmaceuticals AMRX$3.68B2025
Caris Life Sciences CAI$1.13B2025
Immunovant IMVT$957.01M2026
Axsome Therapeutics AXSM$689.81M2025
Chemed CHE$1.54B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on IMVT

Immunovant, figure by figure

Immunovant (IMVT) overview: price, valuation and scorecardAll health care companies by market value

Immunovant total assets: questions and answers

How large are Immunovant's total assets?

Immunovant (IMVT) had total assets of $957.01M at the end of fiscal 2026 (March 31, 2026). That is 23.3% higher than the $776.22M of fiscal 2025.

What is the growth rate of Immunovant's total assets?

Over the five fiscal years to 2026 total assets grew at a compound 18.3% a year.

What are the highest and lowest total assets figures on record for Immunovant?

Across the 8 fiscal years on record (2019–2026), the highest was $957.01M in fiscal 2026 and the lowest $13.83M in fiscal 2019.

How is Immunovant's total assets calculated?

Total assets is everything on the balance sheet at the fiscal year-end — cash, receivables, inventory, property, goodwill and the rest.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Immunovant (IMVT) total assets”, data as of 17 November 2026. https://funkfolio.com/stock/IMVT/total-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.